Pharmacogenomics on Individualized Precise Treatment of Patients With Depression

Based on pharmacogenomics analysis technology, this topic explored its impact onindividualized precise treatment of patients with depression through randomizedcontrolled trials. The study subjects were depression patients from the mental healthresearch center affiliated to Tongji University. The sample size was estimated by PASS21.0.3 software. The sample size of the intervention group and the control group was 60cases each, and SPSS 25.0 software was used for random sampling. The intervention groupcompleted the pharmacogenomic analysis of antidepressants before using them, and selectedappropriate antidepressants according to the characteristics of pharmacokinetics andpharmacodynamics of individual patients, while the control group was administeredaccording to routine treatment. 17 items Hamilton Compression Scale (HAMD‐17), HamiltonAnxiety Scale (HAMA), Dimensional Anhedonia Rating Scale (DARS), Pittsburgh sleep qualityindex (PSQI), Antidepressant Side Effect Checklist (ASEC), Short form 36 item healthsurvey questionnaire (SF‐36) (PDQ) assessment. R Project 4.1.1 software was used forstatistical analysis of data, PLink v1.07 and Haploview software were used forassociation analysis of whole genome and drug efficacy and adverse reactions. To explorethe difference between the reduction rate of drug efficacy and adverse reactions inpatients with depression after pharmacogenomics intervention and conventional treatment.At the same time, we verified and found the gene loci related to the efficacy and adversereactions of antidepressants in the East Asian population.